In conclusion, while the data from animal models and early clinical case reports provide encouraging evidence that prenatal treatment with mTOR inhibitors can reduce the size of cardiac rhabdomyomas and potentially improve immediate outcomes, there remains substantial uncertainty regarding the long-term effects of such interventions on neurodevelopment. The gene discussed is MTOR; the disease is cardiac rhabdomyoma.